221.39MMarket Cap-3.20P/E (TTM)
1.845High1.655Low879.35KVolume1.730Open1.690Pre Close1.55MTurnover1.25%Turnover RatioLossP/E (Static)127.97MShares4.44052wk High-0.23P/B121.77MFloat Cap1.18052wk Low--Dividend TTM70.39MShs Float14.190Historical High--Div YieldTTM11.24%Amplitude1.120Historical Low1.764Avg Price1Lot Size
ProKidney Stock Forum
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...
SEC· 11 mins ago
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
No comment yet